Prosecution Insights
Last updated: April 19, 2026

Ose Immunotherapeutics

3 pending office actions

Portfolio Summary

3
Total Pending OAs
1
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18645607 Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases DENT, ALANA HARRIS 1643 Non-Final OA Apr 25, 2024
18644720 METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER TAYLOR, LIA ELAN 1641 Non-Final OA Apr 24, 2024
17414968 BIFUNCTIONAL MOLECULE DIRECTED AGAINST HUMAN PD-1 CHASE, CAROL ANN 1646 Final Rejection Jun 17, 2021

Managing Ose Immunotherapeutics's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month